about
Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Older men who use computers have lower risk of dementiaGlobal, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transitionAntithrombotic treatment after intracerebral haemorrhageSelective serotonin reuptake inhibitors (SSRIs) for stroke recoverySelective serotonin reuptake inhibitors (SSRIs) for strokeThienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patientsThe benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Prognostic Significance of Right Bundle Branch Block: A Meta-analysis of Prospective Cohort StudiesThe unruptured intracranial aneurysm treatment score: a multidisciplinary consensusSelective serotonin reuptake inhibitors for stroke recovery: a systematic review and meta-analysisCyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of careFailure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practiceAspirin resistancePrevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectivenessIs there a role for laboratory testing to identify patients at risk of aspirin treatment failure?The beginning of the end of warfarin?Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risksReview: dipyridamole given with or without aspirin reduces recurrent strokePreventable stroke and stroke preventionWarfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?Aspirin for the primary prevention of cardiovascular eventsEnhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trialMedical treatment of peripheral arterial diseaseAspirin resistanceAspirin resistance: a new independent predictor of vascular events?Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsAnticoagulants versus antiplatelet agents for acute ischemic strokeAntiplatelet drugsPatients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialSecondary prevention of recurrent strokeAntiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelinesAspirin resistanceAtrial fibrillationPotential new risk factors for ischemic stroke: what is their potential?Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 StudyAssociation between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant dataStroke: working toward a prioritized world agenda
P50
Q21034169-1911AB68-5885-4E8E-9142-6435E888A268Q21134062-EC150F31-8BA9-417A-9229-B55B784535D9Q24170269-A5DBCE89-E3AE-480A-82BD-A64856B4CFC2Q24185972-08B77C94-79A4-4613-AD8C-6834FC72AF4DQ24202939-3ADB20D3-168C-400F-98C5-732CBCFAA2D7Q24235446-BC03DF78-950D-404C-B73D-753E6576A06FQ24240326-EF92E35A-048C-43E3-AA33-15E1B8E9D114Q24595579-109D86A9-F6D3-4B2C-864E-AE6FAB75AA4EQ26782100-DBD811C7-0BFA-4E22-B6A4-598C96B3A61DQ26798104-B2FC73DF-4A6F-4C14-B515-9C22B7B4AE26Q27015758-FF25902A-5869-43EE-9F35-F4AF614505E2Q28165795-4A92E6B3-8C56-48E6-AC6C-95F286022A06Q28166842-ED093AE3-06E2-4C3B-AE20-8F2CA4875A8FQ28167273-5F4B8ED6-D109-4985-969B-18292C1E9518Q28167475-4B2E85A3-922E-4038-8E35-056E2FE8E821Q28167713-895AFBEC-42B6-4EA1-9AE7-4C38ACDAB5D8Q28168289-BCDF77AC-C077-426D-8DA7-F1F6A0F08A7FQ28168824-414533AC-C895-4C33-B1A1-E3EC31AC9A08Q28174032-7246D27C-4142-4102-BDDC-623F1972AD33Q28182292-BE2386F0-7E30-457E-9E2A-8A25FE566B9BQ28187602-23E8EE38-B77A-4ED5-8608-2C23F7B2D3D2Q28193161-89DF18AA-E057-4F75-AA48-2A449D6E46E9Q28193873-6224F1AE-73B5-4080-B3DF-ABC87BF39DD4Q28193982-515959A3-D0CE-497E-8AD8-3C55179DBCE0Q28194759-B6D9C608-5A82-432B-9B84-FE7B82040004Q28195157-F53E0E5B-597C-45AE-A23A-E394E196A891Q28195460-91A950CA-A6F9-4270-9C2F-90F534077E4DQ28195656-C02D66C0-2171-4AAC-9DD6-9FD1C6A78BE6Q28196242-B396D498-0446-450C-8C20-0FBFB6597521Q28196263-3C4C36B0-9BFE-4802-B082-B2566FA430C5Q28210537-64EF68ED-AB4E-46F3-9BBD-6B6322D4E9B2Q28212778-0D7BAA8C-FA20-4398-AFBC-2EBF96F935A4Q28212949-44D9B7D9-E9FE-447F-A83E-3038D89777A4Q28218054-FC4326AB-0A44-4888-80DD-780B9C6376E2Q28219183-63F11640-FEAF-4FCD-B23F-CD2380C7592DQ28249412-66205F34-008F-4172-BDEC-E32C78EE319DQ28391248-9541C16A-A58F-4025-AFF4-53411C72300EQ28392340-79F896D7-CB31-4851-B520-8A0CCE98BCFAQ28655857-674F24FE-E153-47EA-B99A-2BE80D36C87EQ28677503-D1519BDC-625C-41CE-9702-093A93A22988
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Graeme J Hankey
@fr
Graeme J Hankey
@nl
Graeme J Hankey
@sl
Graeme J. Hankey
@en
Graeme J. Hankey
@es
type
label
Graeme J Hankey
@fr
Graeme J Hankey
@nl
Graeme J Hankey
@sl
Graeme J. Hankey
@en
Graeme J. Hankey
@es
altLabel
Graeme Hankey
@en
prefLabel
Graeme J Hankey
@fr
Graeme J Hankey
@nl
Graeme J Hankey
@sl
Graeme J. Hankey
@en
Graeme J. Hankey
@es
P1006
P214
P244
P1006
P1053
H-4968-2014
P106
P1153
57208267059
7102816661
P21
P214
P244
P31
P3829
P4012
P496
0000-0002-6044-7328
P734
P735
P7859
lccn-n94070422